The costs of human Campylobacter infections and sequelae in the Netherlands: A DALY and cost-of-illness approach

2005 ◽  
Vol 2 (1) ◽  
pp. 35-51 ◽  
Author(s):  
M.-J. J. Mangen ◽  
A. H. Havelaar ◽  
R. A. J. A. M. Bernsen ◽  
R. Van Koningsveld ◽  
G. A. De Wit
2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
L Mughini Gras

Abstract In the Netherlands, the Ministry of Health mandates the National Institute for Public Health and the Environment (RIVM) to provide annual updates of the number of illnesses, disease burden and cost-of-illness caused by an agreed-upon standard panel of 14 enteric pathogens. These pathogens are mainly transmitted by food, but also via direct contact with animals, environment-mediated and human-to-human transmission routes. The disease burden is expressed in DALYs (Disability Adjusted Life Years), a metric integrating morbidity and mortality into one unit. Furthermore, the cost-of-illness (COI) related to these 14 pathogens is estimated and expressed in euros. The COI estimates include healthcare costs, the costs for the patient and/or his family, such as travel expenses, as well as costs in other sectors, for example due to productivity losses. Moreover, using different approaches to source attribution, the estimated DALYs and associated COI estimates are attributed to five major transmission pathways (i.e. food, environment, direct animal contact, human-human transmission, and travel) and 11 food groups within the foodborne pathway itself. The most recent DALY and COI estimates referring to the year 2018 show that the 14 pathogens in question are cumulatively responsible for about 11,000 DALYs and €426 million costs for the Dutch population in 2018, with a share for foodborne transmission being estimated at 4,300 DALYs and €171 million costs, which is comparable to previous years. These estimates have been providing vital insights for policy making as to guide public health interventions and resource allocation for over two decades in the Netherlands. Herewith, the approach and outcomes of the burden of disease and COI estimates in the Netherlands will be presented, with a focus on how these estimates enable policy-makers and the scientific community to monitor trends, generate scientific hypotheses, and undertake public health actions.


2002 ◽  
Vol 15 (2) ◽  
pp. 72-77 ◽  
Author(s):  
Johan L. Severens ◽  
Jolanda M. Habraken ◽  
Sanja Duivenvoorden ◽  
Carla M A. Frederiks

Pain ◽  
1999 ◽  
Vol 80 (3) ◽  
pp. 629-636 ◽  
Author(s):  
Jeroen A.J Borghouts ◽  
Bart W Koes ◽  
Hindrik Vondeling ◽  
Lex M Bouter

2011 ◽  
Vol 74 (4) ◽  
pp. 545-552 ◽  
Author(s):  
LUQMAN TARIQ ◽  
JUANITA HAAGSMA ◽  
ARIE HAVELAAR

Infections with Shiga toxin–producing Escherichia coli O157 (STEC O157) are associated with hemorrhagic colitis, hemolytic uremic syndrome (HUS), and end-stage renal disease (ESRD). In the present study, we extend previous estimates of the burden of disease associated with STEC O157 with estimates of the associated cost of illness in The Netherlands. A second-order stochastic simulation model was used to calculate disease burden as disability-adjusted life years (DALYs) and cost of illness (including direct health care costs and indirect non–health care costs). Future burden and costs are presented undiscounted and discounted at annual percentages of 1.5 and 4%, respectively. Annually, approximately 2.100 persons per year experience symptoms of gastroenteritis, leading to 22 cases of HUS and 3 cases of ESRD. The disease burden at the population level was estimated at 133 DALYs (87 DALYs discounted) per year. Total annual undiscounted and discounted costs of illness due to STEC O157 infection for the Dutch society were estimated at €9.1 million and €4.5 million, respectively. Average lifetime undiscounted and discounted costs per case were both €126 for diarrheal illness, both €25,713 for HUS, and €2.76 million and €1.22 million, respectively, for ESRD. The undiscounted and discounted costs per case of diarrheal disease including sequelae were €4,132 and €2,131 , respectively. Compared with other foodborne pathogens, STEC O157 infections result in relatively low burden and low annual costs at the societal level, but the burden and costs per case are high.


2007 ◽  
Vol 22 (6) ◽  
pp. 354-361 ◽  
Author(s):  
A.D.I. van Asselt ◽  
C.D. Dirksen ◽  
A. Arntz ◽  
J.L. Severens

AbstractBackgroundBorderline personality disorder (BPD) is a highly prevalent, chronic condition. Because of its very problematic nature BPD is expected to be associated with substantial societal costs, although this has never been comprehensively assessed.ObjectiveEstimate the societal cost of BPD in the Netherlands.Study DesignWe used a prevalence-based bottom-up approach with a sample of 88 BPD patients who enrolled in a multicenter clinical trial comparing two kinds of outpatient psychotherapy. Costs were assessed by means of a structured interview, covering all healthcare costs, medication, informal care, productivity losses, and out-of-pocket expenses. Only BPD-related costs were included. All costs were expressed in Euros for the year 2000. A bootstrap procedure was performed to determine statistical uncertainty.PatientsAll patients had been diagnosed with BPD using DSM-IV criteria. Mean age was 30.5 years and 92% was female.ResultsBased on a prevalence of 1.1% and an adult population of 11,990,942, we derived that there were 131,900 BPD patients in the Netherlands. Total bootstrapped yearly cost of illness was €2,222,763,789 (€1,372,412,403–€3,260,248,300), only 22% was healthcare-related. Costs per patient were €16,852.ConclusionsAlthough healthcare costs of non-institutionalized Borderline patients might not be disproportionate, total societal costs are substantial.


2015 ◽  
Vol 196 ◽  
pp. 84-93 ◽  
Author(s):  
Marie-Josée J. Mangen ◽  
Martijn Bouwknegt ◽  
Ingrid H.M. Friesema ◽  
Juanita A. Haagsma ◽  
Laetitia M. Kortbeek ◽  
...  

2002 ◽  
Vol 46 (2) ◽  
pp. 168-178 ◽  
Author(s):  
J. J. Polder ◽  
W. J. Meerding ◽  
L. Bonneux ◽  
P. J. van der Maas

Pain ◽  
1995 ◽  
Vol 62 (2) ◽  
pp. 233-240 ◽  
Author(s):  
Maurits W. van Tulder ◽  
Bart W. Koes ◽  
Lex M. Bouter

2017 ◽  
Vol 6 (7) ◽  
pp. 575-581 ◽  
Author(s):  
Rob Ter Heine ◽  
Geert WJ Frederix ◽  
Joost W Geenen ◽  
Anke M Hövels ◽  
Marco van Vulpen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document